Perspectives on Treatment Decisions, Preferences, and Adherence and Long-Term Management in Asthma and COPD: A Qualitative Analysis of Patient, Caregiver, and Healthcare Provider Insights
Miguel Román-Rodríguez,Ilona McMullan,Michelle Warner,Christopher Compton,Ruth Tal-Singer,Jean Orlow,MeiLan Han
DOI: https://doi.org/10.2147/ppa.s467870
2024-11-17
Patient Preference and Adherence
Abstract:Miguel Román-Rodríguez, 1, 2 Ilona McMullan, 3 Michelle Warner, 3 Christopher H Compton, 3 Ruth Tal-Singer, 4 Jean M Orlow, 5 MeiLan K Han 6 1 Centro de Salud Dra. Teresa Pique, Mallorca, Spain; 2 Instituto de Investigación Sanitaria de las Islas Baleares (IdISBa), Mallorca, Spain; 3 GSK, London, UK; 4 Global Allergy and Airways Patient Platform, Vienna, Austria; 5 COPD Patient and COPD Foundation Community Member, Miami, FL, USA; 6 Division of Pulmonary and Critical Care Medicine, University of Michigan School of Medicine, MI, USA Correspondence: Miguel Román-Rodríguez, Centro de Salud Dra. Teresa Pique, Mallorca, Spain, Email Purpose: Asthma and chronic obstructive pulmonary disease (COPD) are associated with substantial morbidity and mortality. This analysis assessed patient, caregiver, and healthcare provider (HCP) opinions regarding asthma and COPD diagnosis and treatment, including inhaler device preferences. Patients and Methods: Insights were from: (1) face-to-face/telephone patient/HCP communications with GSK Global Medical Teams; (2) social media listening; (3) a self-completed online patient/caregiver survey. Data were anonymized and informed consent was provided. Qualitative outputs were extracted, analyzed inductively, and coded per key themes, such as treatment preferences (including perceptions of single inhaler triple therapy [SITT] versus multiple inhaler triple therapy [MITT]) and long-term treatment goals. Data could be assigned to ≥ 1 theme. Results: Overall, 2966 patient and HCP insights (patients, 1150; HCPs, 1816), 988 social media posts, and 44 survey responses (patients, 33; caregivers, 11) were included. Within this analysis, some patients delayed seeking medical advice due to lack of disease understanding and used alternative information sources to better understand treatment options (eg, social media). Patients preferred SITT over MITT in terms of convenience, ease of use, and perceived efficacy; some believed that MITT provided greater coverage due to frequent dosing. HCPs recognized the tendency of patient preferences to drive treatment decisions, and highlighted a reluctance to change therapy among some patients, particularly those well controlled in current therapy. Patients preferred therapies with a shorter onset of action. Patients tended to measure treatment success by symptom improvement and quality of life, whereas HCPs measured treatment success through clinical tests. HCPs reported a lack of patient awareness of the mortality risk associated with COPD. Conclusion: There is discordance between patient and HCP perceptions of treatment success and goals in asthma and COPD. Improved patient education and HCP-patient communication are needed to facilitate meaningful shared decision-making, optimize care plans, and provide early treatment options. Keywords: single inhaler triple therapy, multiple inhaler triple therapy, treatment goals, medical advice, patient education, quality of life Asthma and chronic obstructive pulmonary disease (COPD) are the most common chronic respiratory diseases, affecting a reported 262 million and 300 million patients worldwide, respectively. 1–3 Both diseases represent substantial causes of morbidity and mortality and are associated with significantly impaired quality of life (QoL). Symptoms can impact day- and night-time functioning, have an emotional and social impact, and can affect work productivity and absenteeism. 4,5 These QoL impacts become more pronounced with increasing disease severity. 6,7 Inhaled medications are recommended as maintenance and reliever therapy for both asthma and COPD. 8,9 Though these guideline-recommended therapies have established efficacy in terms of exacerbation control and an acceptable safety profile, 8,9 suboptimal prescribing and inappropriate use can limit their utility. Only ~43% of patients with asthma and ~50% of patients with COPD are thought to be adherent to their prescribed medication. 8,10 Poor adherence is linked to reduced disease control and worse QoL, as well as increased healthcare resource utilization and higher mortality. 1,4,8,11 Reasons for non-adherence can be intentional (for example, due to contraindication or choosing to skip doses when symptoms are not apparent) 12,13 or unintentional (perhaps due to forgetfulness, prohibitive costs, poor disease awareness, or lacking communication with healthcare providers [HCPs]). 9,14,15 Inhaler technique, dosing schedules, and poor physician availability are all key drivers of unintentional non-adherence in asthma and COPD. 11,14< -Abstract Truncated-
medicine, general & internal